William Carroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William Carroll has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Fuson
Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama. 1
17 shared publications - Benjamin B. Kasten
Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, USA
17 shared publications - Benjamin Greene
Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama. 1
17 shared publications - Bharat Panuganti
Department of Otolaryngology–Head and Neck Surgery University of Alabama at Birmingham Birmingham Alabama USA
17 shared publications - Carissa M. Thomas
Department of Otolaryngology University of Alabama at Birmingham Birmingham Alabama USA
17 shared publications - Diana Lin
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
17 shared publications
Latest Publications
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3: Representativeness of Study Participants.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3: Representativeness of Study Participants.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.